Turn Therapeutics appoints former CDC Director Dr. Robert Redfield as Senior Advisor for GX-03

Turn Therapeutics Inc.

Dr. Redfield appointed Senior Advisor of Health Policy and Regulatory Affairs, effective immediately.
He will provide strategic guidance on clinical development and regulatory positioning of lead candidate GX-03.
GX-03 is currently in Phase 2 clinical trials for dermatologic inflammatory conditions.
Dr. Redfield served as 18th Director of the CDC (2018-2021) and led federal public health responses.
Turn Therapeutics is a clinical-stage biotech focused on targeted inflammatory and immunology therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.